Dexcom & Insulet Announce Commercial Agreement to Integrate the Dexcom G6 & Future G7 CGM into Insulet’s Omnipod Horizon™...
February 19 2020 - 7:00AM
Business Wire
- First-ever automated insulin delivery with the tubeless Omnipod
Insulin Management System and personal smartphone control
- Initially compatible with Dexcom G6 CGM, with no fingersticks*
required
- Integration with the next generation Dexcom G7 CGM system, once
available
DexCom, Inc. (NASDAQ: DXCM) and Insulet Corporation (NASDAQ:
PODD), have announced a global commercialization agreement to
combine current and future Dexcom continuous glucose monitoring
systems (CGM) with Insulet’s trusted tubeless insulin delivery Pod
into the Omnipod Horizon™ System for automated insulin delivery,
currently in pivotal trial. Under the terms of the non-exclusive
agreement, the Omnipod Horizon Automated Insulin Delivery (AID)
System will use sensor values from the Dexcom G6 and next
generation G7 CGM systems to predict glucose levels into the future
and automatically adjust the insulin dose required to help reduce
the occurrence of blood glucose highs and lows.
“Everyone at Dexcom is excited to be in the final stages of
integrating Dexcom CGM technology into the Omnipod Horizon System,"
said Kevin Sayer, executive chairman, president and CEO of Dexcom.
"This system will bring together the demonstrated accuracy of
Dexcom CGM with Omnipod’s tubeless insulin delivery Pod which
provides a simple user experience and freedom from injections and
tubes. It will be a truly transformative, automated insulin
delivery system giving more options to people with diabetes.”
“This agreement with Dexcom represents an incredible milestone
for our two organizations in realizing the benefits of
interoperability,” said Shacey Petrovic, president and CEO of
Insulet. “The ability to integrate with new innovation efficiently
will offer consumers the latest and greatest in Pod and sensor
technology, while providing the freedom of choice so they can live
life to the fullest.”
The Omnipod Horizon System will combine market leading
technologies into one integrated system consisting of the Omnipod
tubeless insulin delivery Pod, the Dexcom CGM, and for the first
time, an insulin pump controlled by the convenience of one’s
personal smartphone.
With Dexcom CGM integration, the Omnipod Horizon System requires
no fingersticks* for blood glucose measurement or CGM calibration
and will feature an extended 10-day sensor wear, acetaminophen
blocking†, and the ability to share real-time CGM data with up to
10 followers with the Dexcom Follow mobile app‡. In addition to the
added benefit of automated insulin delivery, the system will also
provide the same proven lifestyle benefits of the current Omnipod
System, including no tubes, waterproof§, and up to three days of
non-stop insulin delivery to make it easy to stay connected and
avoid disruption of insulin delivery during routine activities like
exercising and bathing.
This agreement builds on Dexcom and Insulet’s previously
announced integration efforts and formalizes plans to commercially
launch the Omnipod Horizon System, expected to occur in the second
half of 2020.
About DexCom, Inc.
Dexcom, Inc. empowers people to take control of diabetes through
innovative continuous glucose monitoring (CGM) systems.
Headquartered in San Diego, California, Dexcom has emerged as a
leader of diabetes care technology. By listening to the needs of
users, caregivers, and providers, Dexcom simplifies and improves
diabetes management around the world. For more information about
Dexcom CGM, visit www.dexcom.com.
© 2020 Dexcom, Inc. Dexcom, Dexcom G6 and Dexcom Follow are
registered trademarks of Dexcom, Inc. in the U.S., and may be
registered in other countries. All rights reserved.
About Insulet
Corporation
Insulet Corporation (NASDAQ: PODD), headquartered in
Massachusetts, is an innovative medical device company dedicated to
making the lives of people with diabetes and other conditions
easier through the use of its Omnipod product platform. The Omnipod
Insulin Management System provides a unique alternative to
traditional insulin delivery methods. With its simple, wearable
design, the disposable Pod provides up to three days of non-stop
insulin delivery, without the need to see or handle a needle.
Insulet also leverages the unique design of its Pod, by tailoring
its Omnipod technology platform for the delivery of non-insulin
subcutaneous drugs across other therapeutic areas. For more
information, please visit: www.insulet.com and www.omnipod.com.
© 2020 Insulet Corporation. Omnipod, DASH and Horizon are
trademarks or registered trademarks of Insulet Corporation. All
rights reserved.
* If your glucose alerts and readings from the G6 do not match
symptoms or expectations or you’re taking over the recommended
maximum dosage amount of 1000mg of acetaminophen every 6 hours, use
a blood glucose meter to make diabetes treatment decisions.
†G6 readings can be used to make diabetes treatment decisions
when taking up to a maximum acetaminophen dose of 1,000mg every 6
hours. Taking a higher dose may affect the G6 readings.
‡Separate Follow App required.
§The Pod has a waterproof IP28 rating for up to 25 feet for 60
minutes. The PDM is not waterproof.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20200219005028/en/
Dexcom Investor Contact: Steven R. Pacelli, (858)
200-0200 Executive Vice President, Strategy and Corporate
Development
Dexcom Media Contact: James McIntosh, (619) 884-2118
Senior Manager, Public Relations james.mcintosh@dexcom.com
Insulet Investor Contact: Deborah R. Gordon, (978)
600-7717 Vice President, Investor Relations dgordon@insulet.com
Insulet Media Contact: Angela Wiczek, (978) 932-0611
Director, Corporate Communications awiczek@insulet.com
DexCom (NASDAQ:DXCM)
Historical Stock Chart
From Aug 2024 to Sep 2024
DexCom (NASDAQ:DXCM)
Historical Stock Chart
From Sep 2023 to Sep 2024